Dr. Priya Kishnani
Pediatrics (Pediatrics Physician)
- Medicare participating
At a glance
- Years since graduation
- 39
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 15
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pediatrics Physician primary
NC license 95-00972
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Duke University Hospital Durham, NC
Medical groups
- Duke Health Integrated Practice, Inc (3,185 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 15
- Services billed
- 35
- Patients’ average age
- 61
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Strensiq (asfotase alfa) | 55 |
| Cerdelga (eliglustat tartrate) | 25 |
| Nexviazyme (avalglucosidase alfa-ngpt) | 23 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 10 companies reported 51 payments worth $320,067 in total to this clinician.
| Alnylam Pharmaceuticals Inc. | $220,917 |
|---|---|
| Amicus Therapeutics, Inc. | $34,120 |
| Genzyme Corporation | $28,631 |
| Chiesi USA, Inc. | $10,695 |
| Alexion Pharmaceuticals, Inc. | $7,990 |
| Sanofi US Services Inc. | $6,040 |
| Takeda Pharmaceuticals U.S.A., Inc. | $5,437 |
| Regeneron Pharmaceuticals, Inc. | $3,800 |
| Consulting Fee | $295,699 |
|---|---|
| Travel and Lodging | $10,270 |
| Compensation for services other than consulting (speaking, faculty) | $9,400 |
| Honoraria | $3,795 |
| Food and Beverage | $904 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Alnylam Pharmaceuticals Inc. Dec 1, 2025 | Consulting Fee dividend, profit or | $199,876 |
| Amicus Therapeutics, Inc. Sep 3, 2025 | Consulting Fee POMBILITI; OPFOLDA · POMPE DISEASE | $14,840 |
| Genzyme Corporation Sep 26, 2025 | Consulting Fee | $14,784 |
| Alnylam Pharmaceuticals Inc. Dec 31, 2025 | Consulting Fee | $13,333 |
| Chiesi USA, Inc. Mar 13, 2025 | Compensation for services other than consulting (speaking, faculty) LAMZEDE · ERT FOR ALPHA-MANNOSIDOSIS | $6,900 |
| Alnylam Pharmaceuticals Inc. Mar 31, 2025 | Consulting Fee | $6,667 |
| Sanofi US Services Inc. Apr 3, 2025 | Consulting Fee | $6,040 |
| Amicus Therapeutics, Inc. Jul 23, 2025 | Travel and Lodging travel to Tokyo, Japan | $5,950 |
| Genzyme Corporation Mar 28, 2025 | Consulting Fee | $5,082 |
| Amicus Therapeutics, Inc. Apr 2, 2025 | Consulting Fee POMBILITI; OPFOLDA · POMPE DISEASE | $4,452 |
All 42 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Alnylam Pharmaceuticals Inc. Dec 31, 2025 | Consulting Fee | $13,333 |
| Regeneron Pharmaceuticals, Inc. Dec 19, 2025 | Consulting Fee | $800 |
| Regeneron Pharmaceuticals, Inc. Dec 19, 2025 | Consulting Fee | $800 |
| Regeneron Pharmaceuticals, Inc. Dec 19, 2025 | Consulting Fee | $600 |
| Genzyme Corporation Dec 17, 2025 | Consulting Fee | $378 |
| Alnylam Pharmaceuticals Inc. Dec 15, 2025 | Travel and Lodging travel to Cambridge, MA · in-kind | $569 |
| Alnylam Pharmaceuticals Inc. Dec 15, 2025 | Travel and Lodging travel to Cambridge, MA · in-kind | $211 |
| Alnylam Pharmaceuticals Inc. Dec 15, 2025 | Travel and Lodging travel to Cambridge, MA · in-kind | $179 |
| Alexion Pharmaceuticals, Inc. Dec 4, 2025 | Consulting Fee STRENSIQ · Rare Disease | $2,350 |
| Alnylam Pharmaceuticals Inc. Dec 1, 2025 | Consulting Fee dividend, profit or | $199,876 |
| Genzyme Corporation Nov 20, 2025 | Consulting Fee | $2,310 |
| Amicus Therapeutics, Inc. Nov 12, 2025 | Consulting Fee POMBILITI; OPFOLDA · POMPE DISEASE | $2,968 |
| Amicus Therapeutics, Inc. Oct 23, 2025 | Travel and Lodging POMBILITI; OPFOLDA · POMPE DISEASE · travel to Kyoto, Japan | $159 |
| Amicus Therapeutics, Inc. Oct 23, 2025 | Travel and Lodging POMBILITI; OPFOLDA · POMPE DISEASE · travel to Tokyo, Japan | $155 |
| Genzyme Corporation Sep 26, 2025 | Consulting Fee | $14,784 |
| Genzyme Corporation Sep 20, 2025 | Travel and Lodging travel to Denver, CO · in-kind | $464 |
| Genzyme Corporation Sep 20, 2025 | Travel and Lodging travel to Denver, CO · in-kind | $207 |
| Genzyme Corporation Sep 20, 2025 | Travel and Lodging travel to Denver, CO · in-kind | $157 |
| Amicus Therapeutics, Inc. Sep 3, 2025 | Consulting Fee POMBILITI; OPFOLDA · POMPE DISEASE | $14,840 |
| Amicus Therapeutics, Inc. Aug 31, 2025 | Travel and Lodging travel to Kyoto, Japan | $2,000 |
| Amicus Therapeutics, Inc. Aug 31, 2025 | Consulting Fee | $612 |
| Amicus Therapeutics, Inc. Aug 31, 2025 | Travel and Lodging travel to Kyoto, Japan | $218 |
| Genzyme Corporation Aug 28, 2025 | Consulting Fee | $1,590 |
| Regeneron Pharmaceuticals, Inc. Aug 22, 2025 | Consulting Fee | $800 |
| Regeneron Pharmaceuticals, Inc. Aug 22, 2025 | Consulting Fee | $400 |
| Regeneron Pharmaceuticals, Inc. Aug 22, 2025 | Consulting Fee | $400 |
| Takeda Pharmaceuticals U.S.A., Inc. Aug 21, 2025 | Consulting Fee ELAPRASE · GENETIC DISEASE | $2,400 |
| Genzyme Corporation Aug 16, 2025 | Compensation for services other than consulting (speaking, faculty) NEXVIAZYME · Genetic Disease · in-kind Company’s descriptionIf more than one clinical reprint is received on the same day, the reported transfer of value will reflect the aggregate total. | $1,250 |
| Genzyme Corporation Aug 12, 2025 | Compensation for services other than consulting (speaking, faculty) NEXVIAZYME · Genetic Disease · in-kind Company’s descriptionIf more than one clinical reprint is received on the same day, the reported transfer of value will reflect the aggregate total. | $1,250 |
| Chiesi USA, Inc. Jul 31, 2025 | Honoraria LAMZEDE · ERT FOR ALPHA-MANNOSIDOSIS | $3,795 |
| Genzyme Corporation Jul 25, 2025 | Consulting Fee | $755 |
| Amicus Therapeutics, Inc. Jul 23, 2025 | Travel and Lodging travel to Tokyo, Japan | $5,950 |
| Amicus Therapeutics, Inc. Jul 16, 2025 | Consulting Fee | $2,502 |
| Alexion Pharmaceuticals, Inc. Jun 6, 2025 | Consulting Fee STRENSIQ · Rare Disease | $2,820 |
| ModernaTX, Inc. Apr 18, 2025 | Consulting Fee | $2,320 |
| Sanofi US Services Inc. Apr 3, 2025 | Consulting Fee | $6,040 |
| Amicus Therapeutics, Inc. Apr 2, 2025 | Consulting Fee POMBILITI; OPFOLDA · POMPE DISEASE | $4,452 |
| Alnylam Pharmaceuticals Inc. Mar 31, 2025 | Consulting Fee | $6,667 |
| Genzyme Corporation Mar 28, 2025 | Consulting Fee | $5,082 |
| Chiesi USA, Inc. Mar 13, 2025 | Compensation for services other than consulting (speaking, faculty) LAMZEDE · ERT FOR ALPHA-MANNOSIDOSIS | $6,900 |
| Takeda Pharmaceuticals U.S.A., Inc. Mar 13, 2025 | Consulting Fee | $3,000 |
| Alexion Pharmaceuticals, Inc. Jan 15, 2025 | Consulting Fee STRENSIQ · Rare Disease | $2,820 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 18 industry-funded studies in 2025, from 5 companies. The companies reported $3,157,522 in research payments for these studies, mostly to the institutions running them.
- ESC-Project 1 -Insights and characterization into the central and peripheral nervous system involvement in children with Pompe disease
Genzyme Corporation - ESC-Project 2 -Long-term Follow-up and Treatment Outcomes for Individuals with Pompe Disease: Role of the Immune System
Genzyme Corporation - Evaluation of children with the late-onset Pompe disease GAA variants identified by newborn screening: Guidance for in person or virtual monitoring
Genzyme Corporation - A Study to Assess Safety and Efficacy of Avalglucosidase Alfa Administered Every Other Week in Pediatric Patients With Infantile-onset Pompe Disease Previously Treated With Alglucosidase Alfa
Genzyme Corporation · Active, not recruiting · NCT03019406 - Functional Characterization and Reclassification of Pompe Disease
Amicus Therapeutics, Inc. - A Study to Assess the Long-term Safety and Efficacy of ATB200/AT2221 in Adult Subjects With LOPD
Amicus Therapeutics, Inc. - A Study to Evaluate the Safety, Efficacy, PK, PD and Immunogenicity of Cipaglucosidase Alfa/Miglustat in IOPD Subjects Aged 0 to <18 (ROSSELLA)
Amicus Therapeutics, Inc. - Pompe Disease Registry Protocol
Sanofi US Services Inc. · Recruiting · NCT00231400 - Clinical Study for Treatment-naïve IOPD Babies to Evaluate Efficacy and Safety of ERT With Avalglucosidase Alfa
Genzyme Corporation · Active, not recruiting · NCT04910776 - Gaucher disease outcome survey (gos) an observational, international, multicenter, long-term registry of patients with gaucher disease
Takeda Pharmaceuticals U.S.A., Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.